ArticleFrontiers in immunology2026
Neurological graft-versus-host disease with MOG antibody positivity after allogeneic stem cell transplantation: a case report.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Central nervous system (CNS) involvement is recognized as a distinct manifestation of chronic GVHD (cGVHD). Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an autoimmune disorder targeting the CNS. Therefore, the occasional detection of MOG antibodies in patients with CNS-cGVHD may represent a manifestation within the spectrum of CNS-GVHD. Case presentation: A 22-year-old female with severe aplastic anemia (AA) underwent maternal haploidentical hematopoietic stem cell transplantation (HSCT) in May 2021. During conditioning, she developed acute neurotoxicity. Subsequent complications included acute and chronic GVHD as well as posterior reversible encephalopathy syndrome (PRES). Three months after transplantation, she developed sensory deficits and ataxia, and cervical magnetic resonance imaging revealed inflammatory lesions consistent with cervical myelitis. Comprehensive neuroimmunological evaluation excluded alternative infectious, metabolic, or neoplastic etiologies. Anti-myelin oligodendrocyte glycoprotein (MOG) antibodies were negative by cell-based assay (CBA) and tissue-based assay (TBA), but demonstrated weak, low-titer positivity on live-cell immunofluorescence. Neurological function recovered following treatment with intravenous immunoglobulin (IVIG) and methylprednisolone. Conclusions: This case illustrates low-titer post-HSCT MOG seropositivity detected only by a live cell-based assay in a patient who fulfilled diagnostic criteria for CNS-GVHD. Live cell-based MOG testing may be considered in selected HSCT recipients with unexplained or atypical neuroinflammatory syndromes despite negative conventional assays, with results interpreted cautiously as hypothesis-generating for individualized immunosuppressive management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.